Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05980455

Study of Enterra Programming with Nocturnal Cycling in Gastroparetics

The purpose of this research study is to evaluate if different Enterra® device programming methods active during sleeping hours can maintain gastroparesis-related symptom relief and quality of life measures.

Participants in this study with existing Enterra® devices will be randomly assigned to one of three programming methods that will be active during sleep. Participants will answer daily questions about their gastroparesis symptoms on an application with their phone/tablet. Participants will answer quality of life questionnaires about their gastroparesis symptoms at study visits.

Participants will be involved in the study for up to six months after treatment assignment.

Programming parameters in the study are within currently approved labeling.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Louisville, Louisville, Kentucky, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

In order to be eligible to participate in this study, a participant must meet all of the following criteria:

  • Completed informed consent process with signed and dated informed consent form;
  • Stated willingness to comply with all study procedures and availability for the duration of the study;
  • Male or female, aged ≥18 or ≤70 at time of informed consent;
  • Currently implanted with the Enterra® Therapy System (Enterra® II 37800 neurostimulator);
  • High GES output defined as remaining pulse generator expected life of > 9 months from enrollment and less than 4 years from the time of implant;
  • Stable gastroparesis symptoms, in the opinion of the investigator;
  • On stable medical therapy for gastroparesis symptoms;
  • On stable supplemental nutritional support during the month prior to enrollment;
  • English language comprehension to complete study-required assessments;
  • Reliable access to internet-connected smart device(s) to complete study-required assessments.

A participant who meets any of the following criteria will be excluded from participation in this study:

  • Post-surgical gastroparesis (e.g., fundoplication, Bilroth I or II) or other active stomach or gastrointestinal diseases disorders which could explain symptoms in the opinion of the investigator;
  • Subjects, in the opinion of the investigator, with profound nausea and/or vomiting at night;
  • Subjects, in the opinion of the investigator, with profound gastroparesis symptoms upon waking in the morning;
  • Subjects without a regular and defined sleep schedule;
  • Pregnancy, or subject that intends to become pregnant during participation in the study;
  • Chemical dependency;
  • Enterra lead impedance measurements ≥ 700 Ohms at screening visit;
  • Life expectancy < 1 year from conditions other than GI diseases;
  • Subjects with an underlying disease leading to follow-up by MRI outside of current MR conditional indications;
  • Participation in other clinical studies;
  • Subjects involved in current or past medical-related litigation;
  • Subjects with cognitive impairment or other characteristic that would limit subject's ability to complete study requirements.

Treatment and study plan

Enterra® Therapy System

Device

The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.

Other names: Gastric electrical stimulation

Primary outcomes

  1. Percent Change in Weekly Vomiting Frequency by GCSI-DD

    Time frame: 3 Months, 6 Months

    Less than a 50% increase in GCSI-DD weekly vomiting frequency from baseline

  2. Scoring Change in Nausea Severity by GCSI-DD

    Time frame: 3 Months, 6 Months

    Less than a 1-point increase in GCSI-DD nausea severity from baseline

Secondary outcomes

  1. Mean Change from Baseline in GCSI-DD Total Symptom Score

    Time frame: 3 Months, 6 Months

    Change in GCSI-DD Total Symptom Score from baseline

  2. Mean Change from Baseline in GCSI-DD Nausea Severity

    Time frame: 3 Months, 6 Months

    Change in GCSI-DD nausea severity from baseline

  3. Mean Change from Baseline in GCSI-DD Weekly Vomiting Frequency

    Time frame: 3 Months, 6 Months

    Change in GCSI-DD weekly vomiting frequency from baseline

  4. Mean Change from Baseline in PAGI-QoL Scores

    Time frame: 3 Months, 6 Months

    Change in PAGI-QoL from baseline

  5. Mean Change from Baseline in Quality of Sleep Scores

    Time frame: 3 Months, 6 Months

    Change in Quality of Sleep from baseline

Study contacts

Contact information is provided by the study sponsor or research team.

Jason Hamann, PhD

CONTACT

[email protected]

855-768-3772

Timothy McAllister

CONTACT

[email protected]

855-768-3772

Sponsors and collaborators

Lead sponsor

Enterra Medical, Inc.

Industry

Registry information

Official study title

Randomized Study of Enterra Programming with Nocturnal Cycling in Gastroparetics

Acronym: RESTING

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Aug 8, 2023
Registry last updated
Nov 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.